Literature DB >> 10412003

Cardiovascular regulatory actions of the hypocretins in brain.

W K Samson1, B Gosnell, J K Chang, Z T Resch, T C Murphy.   

Abstract

The hypocretins, also known as the orexins, are alternate translation products of a single gene. The recognition of their production in neurons of the rostral diencephalon, and their axonal localization in brain sites known to be important in the control of appetite, led to the demonstration of their orexogenic actions. However, these peptides are not as potent as other appetite stimulating neuropeptides and they have been localized in areas of brain more related to cardiovascular function. We verified the orexogenic actions of hypocretin-1 (Hcrt-1) and hypocretin-2 (Hcrt-2) in an ad libitum feeding model and identified the threshold dose to be 1 nmol when given into the lateral cerebroventricle (i.c. v.). Even at threshold doses for feeding, both Hcrt-1 and Hcrt-2 given i.c.v. into conscious, unrestrained rats stimulated significant elevations in mean arterial blood pressure, that appeared dose related. These elevations were relatively long lasting, mirroring the time course of a pressor dose of angiotensin II (0.1 nmol i.c.v.); however, the magnitude of blood pressure elevation to hypocretin did not equal that of A II. These data suggest an additional, non-appetitive action of the hypocretins and indicate that the peptide and receptor mapping studies may have predicted important roles for the peptides in the central nervous system control of cardiovascular function. Copyright 1999 Elsevier Science B.V.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10412003     DOI: 10.1016/s0006-8993(99)01457-2

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  60 in total

1.  Cellular localization of orexins in human anterior pituitary.

Authors:  Montserrat Blanco; Rosalía Gallego; Tomás García-Caballero; Carlos Diéguez; Andrés Beiras
Journal:  Histochem Cell Biol       Date:  2003-08-28       Impact factor: 4.304

2.  Effects of sleep on the cardiovascular and thermoregulatory systems: a possible role for hypocretins.

Authors:  H Schwimmer; H M Stauss; F Abboud; S Nishino; E Mignot; J M Zeitzer
Journal:  J Appl Physiol (1985)       Date:  2010-08-12

Review 3.  Energy expenditure: role of orexin.

Authors:  Jennifer A Teske; Vijayakumar Mavanji
Journal:  Vitam Horm       Date:  2012       Impact factor: 3.421

Review 4.  Alcohol use disorder and sleep disturbances: a feed-forward allostatic framework.

Authors:  George F Koob; Ian M Colrain
Journal:  Neuropsychopharmacology       Date:  2019-06-24       Impact factor: 7.853

Review 5.  The brain hypocretins and their receptors: mediators of allostatic arousal.

Authors:  Matthew E Carter; Jana Schaich Borg; Luis de Lecea
Journal:  Curr Opin Pharmacol       Date:  2009-02       Impact factor: 5.547

Review 6.  The hypocretins/orexins: integrators of multiple physiological functions.

Authors:  Jingcheng Li; Zhian Hu; Luis de Lecea
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

7.  Optogenetic identification of hypothalamic orexin neuron projections to paraventricular spinally projecting neurons.

Authors:  Olga Dergacheva; Akihiro Yamanaka; Alan R Schwartz; Vsevolod Y Polotsky; David Mendelowitz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-02-03       Impact factor: 4.733

8.  Direct projections from hypothalamic orexin neurons to brainstem cardiac vagal neurons.

Authors:  Olga Dergacheva; Akihiro Yamanaka; Alan R Schwartz; Vsevolod Y Polotsky; David Mendelowitz
Journal:  Neuroscience       Date:  2016-09-28       Impact factor: 3.590

9.  State-dependent control of lumbar motoneurons by the hypocretinergic system.

Authors:  Jack Yamuy; Simon J Fung; Mingchu Xi; Michael H Chase
Journal:  Exp Neurol       Date:  2009-12-03       Impact factor: 5.330

Review 10.  Hypothalamic orexins/hypocretins as regulators of breathing.

Authors:  Rhîannan H Williams; Denis Burdakov
Journal:  Expert Rev Mol Med       Date:  2008-10-02       Impact factor: 5.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.